<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H9921323CCC7045299BA49A7AC52C4237" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7389 IH: Medicaid VBPs for Patients Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-04-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7389</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220404">April 4, 2022</action-date><action-desc><sponsor name-id="S001180">Mr. Schrader</sponsor> (for himself, <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, and <cosponsor name-id="M001190">Mr. Mullin</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.</official-title></form><legis-body id="H7056663214E14AE080D8563C2B48F1DF" style="OLC"><section id="H14AFD0938674422991D914B97CAEA717" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicaid VBPs for Patients Act</short-title></quote> or the <quote><short-title>MVP Act</short-title></quote>.</text></section><section id="H2279C616636E404898818387BB587D7A"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">The Congress finds the following:</text><paragraph id="HECB84E803FDB44FD959D68CEE72B3F1C"><enum>(1)</enum><text>Value-based payment (VBP) arrangements are a critical component of a modernized reimbursement system. By codifying elements of the recently finalized “multiple best price” policies of the Centers for Medicare &amp; Medicaid Services, Congress is enshrining a sustainable and flexible payment approach for innovative treatments and cures.</text></paragraph><paragraph id="HE3E54384E37D4E448AF253AA9FE85153"><enum>(2)</enum><text>Many of these treatments, including gene therapies, are different from traditional pharmaceutical and biologic products in that they can offer long-lasting—sometimes lifelong—benefits for patients and long-term value for the health care system alike.</text></paragraph><paragraph id="H79312E6E78A2416394D7E89465120450"><enum>(3)</enum><text>There are hundreds of innovative, curative, and life-changing treatments currently in development in the United States. However, the current reimbursement structure was not designed with these therapies in mind, and allowing for innovative payment arrangements will spur greater development and access to future cures and treatments.</text></paragraph><paragraph id="H666657BE6D3C4EE0A7F0542B66D0E1C1"><enum>(4)</enum><text>Medicaid is currently losing out on innovative ways to ensure patients have access to these treatments, while private payors continue to see the value provided through flexible payment arrangements.</text></paragraph><paragraph id="H3637BC40B6F84B84970D09CEF580E871"><enum>(5)</enum><text>VBP arrangements include the ability to pay based on evidence-based outcomes and, over time, spreading the risk across all entities involved in the contract and ensuring that these often costly treatments are accessible.</text></paragraph><paragraph id="HC195CCFF082C49529C652C4A45B42FC1"><enum>(6)</enum><text>Evidence-based outcomes can demonstrate decreased cost to the health system and to patients, including reduced hospitalizations and lower utilization of other health care expenditures, including lab work, other medications, and office visits.</text></paragraph><paragraph id="HC822D445BA254624B70DE89A39CAAE03"><enum>(7)</enum><text>By allowing VBPs in Medicaid, the health care system will continue to move towards quality over quantity, holding manufacturers and providers accountable for the best treatment for every patient.</text></paragraph></section><section id="HDF40DCF44C85475281A534D975894460"><enum>3.</enum><header>Codifying value-based purchasing arrangements under Medicaid and reforms related to price reporting under such arrangements</header><subsection id="H27175ADF3AB04D048FD55F69FA7DA6E5"><enum>(a)</enum><header>Codifying the VBP rule</header><text display-inline="yes-display-inline">The revision to section 447.505(a) of title 42, Code of Federal Regulations related to the inclusion of varying best price points available under a value-based purchasing arrangement (as defined in section 1927(k)(12) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(12)</external-xref>, as added by subsection (d) of this section) for a single dosage form and strength of a covered outpatient drug if a manufacturer offers such pricing structure to all States, as published by the Secretary of Health and Human Services on December 31, 2020 (85 Federal Register 87000), shall have the force and effect of law.</text></subsection><subsection id="H5ABFD2CC8E9D44338A253D0B8EDB23EF"><enum>(b)</enum><header>Quarterly reporting obligation</header><paragraph id="H3186F86589E34C2A8A7EDB4097566C94"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1927(b)(3)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(b)(3)(A)</external-xref>) is amended—</text><subparagraph id="HACBC59CD85544EFE80A01895E026CD7D" display-inline="no-display-inline"><enum>(A)</enum><text>in clause (iv), by striking at the end <quote>and</quote>;</text></subparagraph><subparagraph id="H78869BB4AD62405EB6576694A8516984"><enum>(B)</enum><text>in clause (v), by striking at the end the period and inserting <quote>; and</quote>; </text></subparagraph><subparagraph id="HA5ACC50C82A64255AE80DA6D942F0783"><enum>(C)</enum><text>by inserting after clause (v) the following new clause:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H2E1CE4A9682D4AC1A36BFB7BBAC1CA47"><clause id="HCDA772C74D9F4DF38D10658675D229D3"><enum>(vi)</enum><text display-inline="yes-display-inline">for calendar quarters beginning on or after July 1, 2022, in conjunction with reporting required under clause (i), in the case of a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in subsection (k)(12)) made available by the manufacturer to a State plan—</text><subclause id="HFF99B735284C4EE384211FE1596833A8"><enum>(I)</enum><text>the pricing structure for such drug based on pre-defined outcomes or measures specified in such value-based purchasing arrangement; and</text></subclause><subclause id="HA1F7FE2119C14305ADC9AF5A4938FA16"><enum>(II)</enum><text>the best price for such covered outpatient drug outside of a value-based purchasing arrangement, which in the event such drug is sold exclusively through such an arrangement, means the lowest price available net of any discounts or offsets that are unrelated to a refund, rebate, reimbursement, free item, withholding, or repayment made under a value-based purchasing arrangement for such drug.</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="HEFFCD4CB12C74089B4148F7F8049DD19"><enum>(D)</enum><text>by adding at the end of the flush left matter at the end the following new sentence: <quote>Information reported with respect to a rebate period under clause (i)(I) relating to average manufacturer price and clause (i)(II) relating to best price shall be updated for such rebate period if, subsequent to the date such information was reported, cumulative discounts, rebates, or other arrangements adjust such average price actually realized or best price available to the extent that such cumulative discounts, rebates, or other arrangements are not excluded under this section from the determination of average manufacturer price or best price.</quote></text></subparagraph></paragraph><paragraph id="H7A264C7D5DBC4B638B17DC10F9B73A0D"><enum>(2)</enum><header>Rules of construction</header><text>Nothing in the amendments made by paragraph (1) shall be construed as—</text><subparagraph id="HC59123EE58E843268F3D0C188DC3BD8C"><enum>(A)</enum><text>requiring—</text><clause id="HEBC8CDEC84AE430D82D7C878778C1E50"><enum>(i)</enum><text>a State to enter into a value-based purchasing arrangement with a manufacturer for a covered outpatient drug; or</text></clause><clause id="H136AEA70835040B98E6B876C1D8DA9F8"><enum>(ii)</enum><text>a manufacturer to enter into a value-based purchasing arrangement with a State for a covered outpatient drug;</text></clause></subparagraph><subparagraph id="H2982C395CD3242D38918CF73EE9DC32D"><enum>(B)</enum><text>prohibiting a manufacturer from treating a value-based purchasing arrangement as a bundled sale; or</text></subparagraph><subparagraph id="HC2BDBCA6FC534C93AD34D792726703DA"><enum>(C)</enum><text display-inline="yes-display-inline">precluding the execution of a supplemental rebate agreement, as provided in section 1927(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(a)(1)</external-xref>), for a covered outpatient drug sold under a value-based purchasing arrangement.</text></subparagraph></paragraph></subsection><subsection id="H2698961BFAE44D6BBE34E0C377A5F2FA"><enum>(c)</enum><header>Definition of average manufacturer price</header><text>Section 1927(k)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(1)</external-xref>) is amended—</text><paragraph id="H0ECC1104BD02435296C0481D175DE125"><enum>(1)</enum><text>in subparagraph (B)(i)—</text><subparagraph id="H1B64F2D89F4C42829B22E5ACAEC0DD82"><enum>(A)</enum><text>in subclause (IV), by striking at the end <quote>and</quote>;</text></subparagraph><subparagraph id="H22C2F584FF54494B8485416C5702BBD2"><enum>(B)</enum><text>in subclause (V), by striking the period at the end and inserting <quote>; and</quote>; and</text></subparagraph><subparagraph id="H0661BDDB8B9040D5ADAF45F1F776E1D3"><enum>(C)</enum><text>by adding at the end the following new subclause:</text><quoted-block id="HE76ED83473904825A6F85019D609F1A3" style="OLC"><subclause id="H69C98FB437244EFB8236B1368156CBB0"><enum>(VI)</enum><text>in accordance with subsection (b)(3)(A)(vi), with respect to such covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period—</text><item id="HC6AA66FF18974BE09FAA0C5AAFC2BAED"><enum>(aa)</enum><text>a refund, rebate, reimbursement, or free goods from the manufacturer or third party on behalf of the manufacturer; or</text></item><item id="HCD8FE2A7EE03482D9F02BDACBB855F2C"><enum>(bb)</enum><text>the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer;</text></item><continuation-text continuation-text-level="subclause">that is triggered by a patient who fails to achieve outcomes or measures defined under the terms of such value-based purchasing arrangement during the period for which such agreement is effective.</continuation-text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HB8620B0BE054466BB5F2CDE992C368BA"><enum>(2)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block id="HECBAE851802C481A97D440C78E5F8B56" style="OLC"><subparagraph id="H14F89A51741C4C29A141655921BF2B7C"><enum>(D)</enum><header>Special rule for certain value-based purchasing arrangements</header><text>For purposes of subparagraph (A), in determining the average price paid to the manufacturer for a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) that provides that payment for such drug is made in installments over the course of such agreement, such price shall be determined as if the aggregate price per the terms of the agreement was paid in full in the first installment during the rebate period.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HA91437BDAC4247CC949A9A7712D89EBE"><enum>(d)</enum><header>Definition of value-Based purchasing arrangement</header><text>Section 1927(k) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)</external-xref>) shall be amended by adding at the end the following paragraph:</text><quoted-block id="H4A121720CB8043288685DF6A393F8FA9" style="OLC"><paragraph id="HCA180DAB166B43C9B77E5E2BA83EC461"><enum>(12)</enum><header>Value-Based Purchasing Arrangement</header><text>The term <term>value-based purchasing arrangement</term> means an arrangement or agreement intended to align pricing or payments to an observed or expected therapeutic or clinical value in a select population and includes—</text><subparagraph id="H459D3C3664774E5BB9225BC51EB6AE40"><enum>(A)</enum><text>evidence-based measures, which substantially link the cost of a covered outpatient drug to existing evidence of effectiveness and potential value for specific uses of that product; or</text></subparagraph><subparagraph id="H882E4A29A8674D2FBE5FDA870736638C"><enum>(B)</enum><text>outcomes-based measures, which substantially link payment for the covered outpatient drug to that of the drug’s actual performance in patient or a population, or a reduction in other medical expenses.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HCD858FD5776E415D9EC867A53105C696"><enum>(e)</enum><header>Effective date</header><text>The amendments made by this section shall apply beginning on July 1, 2022.</text></subsection></section><section id="H8064F0E83A464EB9BDE5C866CDB16766"><enum>4.</enum><header>Remuneration in Federal health care programs</header><subsection id="HD0B6C00EAB6A49C78615C0A5FC612057"><enum>(a)</enum><header>In general</header><text>Section 1128B(b)(3) of the Social Security Act (42 U.S.C. 1320a–7b(b)(3)) is amended—</text><paragraph id="H71EE620FB60547188D55FADAE1EB6BAD"><enum>(1)</enum><text>in subclause (J)—</text><subparagraph id="H9A05E92FC8594CDB805864EC3114066F"><enum>(A)</enum><text>by moving the left margin of such subparagraph 2 ems to the left; and</text></subparagraph><subparagraph id="HA18D56ABD9934865B76B4541600EB246"><enum>(B)</enum><text>by striking <quote>and</quote> after the semicolon at the end;</text></subparagraph></paragraph><paragraph id="H0B2149E72837431AB197BFC8583C3C88"><enum>(2)</enum><text>in subclause (K)—</text><subparagraph id="H28FB13C66E1A45129F1EF66A8CD8570D"><enum>(A)</enum><text>by moving the left margin of such subparagraph 2 ems to the left; and</text></subparagraph><subparagraph id="H0E3A622841CF46E199CCA8C54AE20AAD"><enum>(B)</enum><text>by striking the period at the end and inserting <quote>; and</quote>; and</text></subparagraph></paragraph><paragraph id="HCFCE931D9D534128B720B0BC6EF93DFF"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block id="HB6917B357E2642FEA19BA245D0A01C5A" style="OLC"><subparagraph id="H1AFAF094AB31454E88E25B9458F6C0F8"><enum>(L)</enum><text>any remuneration provided by a manufacturer or third party on behalf of a manufacturer to a plan under a value-based purchasing arrangement (as defined in section 1927(k)(12)) in the case a patient fails to achieve outcomes or measures defined in such arrangement following the administration of a covered outpatient drug (as defined in section 1927(k)(2)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HF8562CAC3C75435EB584FB94FB66099D"><enum>(b)</enum><header>Effective date</header><text>The amendments made by this section shall apply beginning on July 1, 2022.</text></subsection></section><section id="HFBAE47C8DF97438EB162699E3DE70BFD"><enum>5.</enum><header>GAO study and report on use of value-based purchasing arrangements</header><subsection id="HE7D5C2F90CD44D38969266DFDCF57BC8"><enum>(a)</enum><header>Study</header><text>The Comptroller General of the United States shall conduct a study on the extent to which value-based purchasing arrangements (as defined in section 1927(k)(12) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(12)</external-xref>) facilitate patient access to covered outpatient drugs, improve patient outcomes, lower overall health system costs, and lower costs for patients in Federal health care programs. In conducting such study, the Comptroller General shall—</text><paragraph id="HF116DE57F7234F67901F8BFC7E485D99"><enum>(1)</enum><text>study the impact of this Act on—</text><subparagraph id="H2B01C48C38BF4CA195B596F7ACB0A768" display-inline="no-display-inline"><enum>(A)</enum><text>access to transformative therapies, including rare disease gene therapies, generally;</text></subparagraph><subparagraph id="HB0BDE275102A4DACA66BC823F98332D7"><enum>(B)</enum><text>mitigating socioeconomic disparities in accessing covered outpatient drugs sold under value-based purchasing arrangements through its requirement that State Medicaid programs have access to the same value-based purchasing arrangement pricing structure that are available in the commercial market for such drugs; and</text></subparagraph><subparagraph id="H8C692D1298F9489188477917DC259836"><enum>(C)</enum><text>the Medicaid drug rebate program under section 1927 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8</external-xref>), the 340B drug pricing program under section 340B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/256b">42 U.S.C. 256b</external-xref>), and part B of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395j">42 U.S.C. 1395j et seq.</external-xref>), including compliance with such programs; and</text></subparagraph></paragraph><paragraph id="H8101E154A6824A78B4F0BA93AB59E351"><enum>(2)</enum><text display-inline="yes-display-inline">using data submitted pursuant to clause (vi) of section 1927(b)(3)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(b)(3)(A)</external-xref>), as added by section 3 of this Act, analyze all the types of value-based purchasing arrangement pricing structures, which structures are working well (as measured by price and ease of implementing), and which need improvement.</text></paragraph></subsection><subsection id="H0178C9DAB4D24CC7A370A4C625701E5E"><enum>(b)</enum><header>Report</header><text>Not later than June 30, 2027, the Comptroller General of the United States shall submit to Congress a report containing the results of the study conducted under subsection (a). </text></subsection></section></legis-body></bill> 

